Acquired BRAFi Resistance Increases Melanoma Cell Sensitivity to Metabolic Targeting with Metformin
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27188088 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von María Florencia Arbe und 3 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Transferencia Genética y Laboratorio de Metabolismo Tumoral, Área Investigación, Instituto de Oncología Ángel H. Roffo, Facultad de Medicin…. Hauptthemen laut MEDLINE: Metformin, Drug Resistance, Neoplasm, Melanoma, Proto-Oncogene Proteins B-raf. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Nacional de Investigaciones Científicas y Técnicas, Argentinian National Agency for Scientific and Technological Promotion, Agencia Nacional para la Promoción Científica y Tecnológica.
Abstract (Originalsprache)
The use of BRAF inhibitors (BRAFi) for the targeted inhibition of the MAPK pathway represents a cornerstone of treatment for BRAFV600E-mutant melanoma. However, the rapid emergence of drug resistance remains a major clinical challenge. Mounting evidence indicates that therapy resistance is driven by both phenotypic plasticity and metabolic reprogramming. This study aimed to investigate the molecular, phenotypic, and metabolic adaptations underlying acquired resistance to the BRAFi GSK2118436 in A375 melanoma cells. BRAFi-resistant cells (A375-R) displayed cross-resistance to additional BRAFi and MEK inhibitors and clear features of epithelial–mesenchymal transition (EMT), including decreased E-cadherin, increased vimentin, and inhibitor-dependent spheroid compaction. Among the multiple metabolic modulators evaluated, inhibitors of mitochondrial respiration—particularly metformin and antimycin A—selectively impaired viability, clonogenicity, sphere formation and 3D growth of resistant cells. Importantly, while simultaneous BRAFi–metformin combination caused mostly antagonist effects, a sequential regimen (BRAFi followed by metformin) elicited additive/synergistic cytotoxicity in both 2D and 3D models. Collectively, these findings show that BRAFi resistance is driven by coordinated EMT and metabolic rewiring toward OXPHOS dependency and suggest that sequential metabolic targeting is an effective strategy to overcome therapy resistance in melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidad de Transferencia Genética y Laboratorio de Metabolismo Tumoral, Área Investigación, Instituto de Oncología Ángel H. Roffo, Facultad de Medicina, Universidad de Buenos Aires, Av. San Martín 5481, Buenos Aires C141…
ORCID-Profile: Marcela Solange Villaverde
Förderung
- Consejo Nacional de Investigaciones Científicas y Técnicas
- Argentinian National Agency for Scientific and Technological Promotion
- Agencia Nacional para la Promoción Científica y Tecnológica
Zitieren
APA
Arbe, M. F., Glikin, G. C., Finocchiaro, L. M. E., & Villaverde, M. S. (2026). Acquired BRAFi Resistance Increases Melanoma Cell Sensitivity to Metabolic Targeting with Metformin. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27188088
Vancouver
Arbe MF, Glikin GC, Finocchiaro LME, Villaverde MS. Acquired BRAFi Resistance Increases Melanoma Cell Sensitivity to Metabolic Targeting with Metformin. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27188088
BibTeX
@article{Arbe2026,
author = {Arbe, María Florencia and Glikin, Gerardo Claudio and Finocchiaro, Liliana María Elena and Villaverde, Marcela Solange},
title = {Acquired BRAFi Resistance Increases Melanoma Cell Sensitivity to Metabolic Targeting with Metformin},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27188088}
}
EUVIMED